Companies
CureVac
mRNA therapeutics pioneer acquired by BioNTech (Jan 2025) — CV8102 adjuvant and thermostable mRNA formulation technology for vaccines and oncology.
- Country
- Germany
- Revenue
- ~$50M
- Employees
- ~200 emp
GMP EU
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | €438.3 million cash position as of March 31, 2025; €481.7 million cash position as of December 31, 2024 | curevac.com |
| Production site | Tübingen, Germany (headquarters and manufacturing), with additional operations in the Netherlands, Belgium, Switzerland, and the U.S. | synapse.patsnap.com · curevac.com |
| Certification | Manufacturing license for mRNA construct (Nov 2023), drug substance framework manufacturing license (Dec 2023), and updated manufacturing license for oncology (July 2024) for The RNA Printer® | curevac.com |
| Revenue | €535.2 million for the full year 2024; €14.5 million for the fourth quarter of 2024 | curevac.com |
| Headcount | Approximate average workforce of 1,088 over 2024; company completed a 30% workforce reduction in 2024 | curevac.com |
| Capacity | Deprioritized commercial large-scale manufacturing; focus on small-scale clinical trial supply using The RNA Printer® and existing GMP facilities (GMP III + GMP IV) | curevac.com |
Independent sources: synapse.patsnap.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| mRNA platforms & LNP delivery | therapeutics-platforms | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.